COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series
COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series
Simple item page
Full item details
- creativework.keywords - en
- Health sciences
- Public health
- Immunology
- Immune response
- Microbiology
- dc.contributor.author
- Walmsley, Sharon L.
- Szadkowski, Leah
- Wouters, Bradly
- Clarke, Rosemarie
- Colwill, Karen
- Rochon, Paula
- Brudno, Michael
- Ravindran, Rizanni
- Raboud, Janet
- McGeer, Allison
- Oza, Amit
- Graham, Christopher
- Silva, Amanda
- Manase, Dorin
- Maksymowsky, Peter
- Parente, Laura
- Dayam, Roaya Monica
- Simpson, Jacqueline
- Pasculescu, Adrian
- Gingras, Anne-Claude
- dc.date.accepted
- 2023-03-22
- dc.date.accessioned
- 2024-01-04T20:15:06Z
- dc.date.available
- 2024-01-04T20:15:06Z
- dc.date.issued
- 2023-04-21
- dc.date.submitted
- 2022-12-23
- dc.description.abstract - en
- We report a decentralized prospective cohort study of self-reported adverse events and antibody responses to COVID vaccines derived from dried blood spots. Data are presented for 911 older (aged >70 years) and 375 younger (30–50 years) recruits to 48 weeks after the primary vaccine series. After a single vaccine, 83% younger and 45% older participants had overall seropositivity (p < 0.0001) increasing to 100/98% with the second dose, respectively (p = 0.084). A cancer diagnosis (p = 0.009), no mRNA-1273 vaccine doses (p <0 .0001), and older age (p <0 .0001) predicted lower responses. Antibody levels declined in both cohorts at 12 and 24 weeks increasing with booster doses. At 48 weeks, for participants with 3 vaccine doses, the median antibody levels were higher in the older cohort (p = 0.04) with any dose of mRNA-1273 (p <0 .0001) and with COVID infection (p <0 .001). The vaccines were well tolerated. Breakthrough COVID infections were uncommon (16% older cohort, 29% younger cohort; p < 0.0001) and mild.
- dc.identifier.citation
- Walmsley SL, Szadkowski L, Wouters B, et al. COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series. iScience. 2023;26(4):106506. doi:https://doi.org/10.1016/j.isci.2023.106506
- dc.identifier.doi
- https://doi.org/10.1016/j.isci.2023.106506
- dc.identifier.issn
- 2589-0042
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/1452
- dc.language.iso
- en
- dc.publisher
- Cell Press
- dc.rights - en
- Creative Commons Attribution 4.0 International (CC BY 4.0)
- dc.rights - fr
- Creative Commons Attribution 4.0 International (CC BY 4.0)
- dc.rights.openaccesslevel - en
- Gold
- dc.rights.openaccesslevel - fr
- Or
- dc.rights.uri - en
- https://creativecommons.org/licenses/by/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by/4.0/deed.fr
- dc.subject - en
- Health
- dc.subject - fr
- Santé
- dc.subject.en - en
- Health
- dc.subject.fr - fr
- Santé
- dc.title - en
- COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series
- dc.type - en
- Article
- dc.type - fr
- Article
- local.acceptedmanuscript.articlenum
- 106506
- local.article.journalissue
- 4
- local.article.journaltitle
- iScience
- local.article.journalvolume
- 26
- local.peerreview - en
- Yes
- local.peerreview - fr
- Oui
Download(s)
Original bundle
1 - 1 of 1
Name: walmsley-covid-19-antibody-responses-community-dwelling-adults-48-weeks-post-primary-series.pdf
Size: 4.04 MB
Format: PDF
Collection(s)